Valuation : Lexaria Corp

Market Cap 19.3M 16.63M 15.59M 14.23M 26.82M 1.84B 26.9M 185M 72.18M 931M 72.47M 70.89M 3.09B P/E 2026 *
-2.88x
P/E 2027 * -2.51x
Enterprise Value 19.3M 16.63M 15.59M 14.23M 26.82M 1.84B 26.9M 185M 72.18M 931M 72.47M 70.89M 3.09B EV / Sales 2026 *
965x
EV / Sales 2027 * 13.8x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2024
Director of Finance/CFO 66 01/10/2024
President 55 15/04/2015
Director TitleAgeSince
Chairman 65 26/10/2006
Director/Board Member 72 08/07/2011
Director/Board Member 55 29/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-6.99%+59.53%+110.81% 1,048B
-0.25%-1.73%+51.36%+61.64% 640B
-0.87%-3.01%+23.60%+74.31% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+10.79% 255B
-1.32%-1.58%+51.40%+68.55% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.46%-0.40%+29.30%+88.91% 185B
Average -0.93%-0.72%+28.69%+48.44% 409.07B
Weighted average by Cap. -0.82%-1.92%+38.13%+64.81%

Financials

2026 *2027 *
Net sales 20K 17.23K 16.16K 14.75K 27.79K 1.91M 27.88K 192K 74.8K 965K 75.09K 73.46K 3.2M 1.4M 1.21M 1.13M 1.03M 1.95M 134M 1.96M 13.45M 5.25M 67.69M 5.27M 5.15M 224M
Net income -6.64M -5.72M -5.36M -4.9M -9.22M -635M -9.25M -63.64M -24.83M -320M -24.93M -24.38M -1.06B -8.95M -7.71M -7.23M -6.6M -12.43M -855M -12.47M -85.76M -33.46M -432M -33.59M -32.86M -1.43B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-